TOP > 外国特許検索 > ANTI-HIV MONOCLONAL ANTIBODY

ANTI-HIV MONOCLONAL ANTIBODY UPDATE

外国特許コード F110002691
整理番号 S2007-1203-C0
掲載日 2011年4月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2008JP071035
国際公開番号 WO 2009066702
国際出願日 平成20年11月19日(2008.11.19)
国際公開日 平成21年5月28日(2009.5.28)
優先権データ
  • 特願2007-299083 (2007.11.19) JP
発明の名称 (英語) ANTI-HIV MONOCLONAL ANTIBODY UPDATE
発明の概要(英語) Disclosed is a monoclonal antibody capable of recognizing V3 loop in an envelope glycoprotein gp120 of an AIDS virus, which is selected from the following antibodies (a) and (b): (a) an antibody which has the amino acid sequence depicted in SEQ ID NO:1 as the amino acid sequence for the H-chain variable region (VH) and the amino acid sequence depicted in SEQ ID NO:2 as the amino acid sequence for the L-chain variable region (VL); and (b) an antibody which has the amino acid sequence depicted in SEQ ID NO:3 as the amino acid sequence for the H-chain variable region (VH) and the amino acid sequence depicted in SEQ ID NO:4 as the amino acid sequence for the L-chain variable region (VL).
従来技術、競合技術の概要(英語) BACKGROUND ART
Acquired immune deficiency syndrome (Acquired Immunodeficiency Syndrome; AIDS) is, human immunodeficiency virus (Human Immunodeficiency virus; HIV) chronically infected with lentiviruses that caused by a disease state. In recent years, an anti-viral agent for inhibiting the growth of HIV have been developed, and it becomes possible to inhibit the occurrence AIDS. However, a potent anti-viral agent may be used by the displacing HIV and it will be difficult, may still be are incapable of anti-viral treatments. On the other hand, long-term use of antiviral drugs by drug resistance problems such as toxicity or chronic virus is also apparent, the current antiviral therapy is still insufficient state. In addition, anti-viral drugs are expensive, long-term use in developing countries is substantially impossible. Due to these circumstances, the development of vaccines and infestation prevention includes the world is high and, in addition to the development of therapeutics and new side effects are also demanded.
HIV monoclonal antibody neutralized the infection of various kinds have been reported (Burton, DR. et al., Nat.Immunol. 5, p233-236, 2004; Zolla-Pazner, S. et al., Nat.Rev.Immunol. 4, p199-210, 2004; Eda, Y. et al., J.Virol. 80: 5552-5562, 2006). The external coating is roughly divided into their target molecule V1/V2 of the gp120 protein, such as variable region antibodies against V3, antibodies to the CD4 binding site (CD4bs), CD4i (CD4-gp120 binding that occur after the epitope) antibodies and the like. On the other hand, transmembrane protein, gp41 of the neutralizing activity of antibodies reactive to MPR(membrane proximal region) also has been introduced. Among these, have been shown and cross-reaction of the antibody and the V3 KD-247 447-52D, b12 CD4bs antibody, 4E10 antibody and gp41-MPR 2F5, and 2G12 anti-carbohydrate antibodies. V3 Antibody cross-reactivity is to be appreciated that the reaction is limited to the viral strain can be a problem. On the other hand, a number of clinical isolates were gp41-MPR antibody is cross-reaction is observed, the last few years have been noted, they are recently, lymphocytes of the host cell lipids have been shown to cross-reactivity, of autoantibodies to actually HIV cross-react with gp41 was found to be those. In addition, as long as CD3 is also b12 amino acid 18, cross-reactivity to self-antigens suggested (Haynes, BF et al., Science 308, p1906-1908, 2005).
Burton, DR. et al., Nat.Immunol. 5, p233-236, 2004
Zolla-Pazner, S. et al., Nat.Rev.Immunol. 4, p199-210, 2004
Eda, Y. et al., J.Virol. 80:5552-5562, 2006
Haynes, BF et al., Science 308, p1906-1908, 2005
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • MATSUSHITA, Shuzo
  • YOSHIMURA, Kazuhisa
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close